世界病毒学杂志(英文版)最新文献

{"title":"Hantavirus infections: A growing global health concern.","authors":"Praveen Kumar Uppala, Sita K Karanam, Naga Vishnu Kandra, Sandhya Edhi","doi":"10.5501/wjv.120334","DOIUrl":"10.5501/wjv.120334","url":null,"abstract":"<p><p>Hantaviruses are increasingly regarded as an important emerging risk to global health, with an estimated annual impact on more than 200000 people worldwide. These pathogens are single-stranded RNA viruses belonging to the family <i>Han</i> <i>taviridae</i> and are known to cause two major clinical syndromes in humans: Hemorrhagic fever with renal syndrome (HFRS) and hantavirus pulmonary syndrome (HPS). The so-called old world hantaviruses, which are associated with HFRS, are predominantly distributed across Asia, Europe, and parts of Africa. In contrast, new world hantaviruses, responsible for HPS, are largely confined to North and South America. Each year, approximately 150000-200000 HFRS cases require hospitalization globally, with the greatest burden occurring in developing regions. The mortality rate of HFRS ranges from below 1% to about 12%, depending on the infecting strain. Both disease forms are characterized by increased capillary permeability, leading to clinical features such as hypotension, thrombocytopenia, and leukocytosis. While HFRS has a broader geographic distribution, HPS carries a higher risk of death. Moreover, the detection of new viral strains and the steady rise in reported cases have intensified global concern. Enhancing surveillance systems and expanding laboratory diagnostic capacity are therefore essential for effective monitoring and control of hantavirus diseases.</p>","PeriodicalId":61903,"journal":{"name":"世界病毒学杂志(英文版)","volume":"15 3","pages":"120334"},"PeriodicalIF":0.0,"publicationDate":"2026-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13598482/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149042044","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Junín virus and Argentine haemorrhagic fever: Virology, pathogenesis, diagnosis, and prevention strategies.","authors":"Sita Kumari Karanam, Praveen Kumar Uppala, Naga Vishnu Kandra, Sandhya Edhi","doi":"10.5501/wjv.121066","DOIUrl":"10.5501/wjv.121066","url":null,"abstract":"<p><p>The Junin virus (JUNV) is mainly perpetuated in nature by rodent reservoirs, especially <i>Calomys musculinus</i>, and is transmitted to humans through aerosolization of contaminated rodent excreta. Clinical presentation of Argentine haemorrhagic fever (AHF) is characterized by an incubation period of about 7-14 days and several clinical manifestations such as fever, malaise, hematological abnormalities, hemorrhagic symptoms and neurological complications. The current review summarizes the current knowledge on the taxonomy, structure, genome structure, transmission dynamics, pathogenesis, clinical syndrome, and diagnostic methods that are related to JUNV infection. Special emphasis is on the progress in the sphere of molecular diagnostics, immune plasma therapy, and antiviral studies. The introduction of the Candid #1 live attenuated vaccine is a significant step towards the prevention of the AHF and has greatly reduced the prevalence of the disease among the endemic populations. Recent scientific advances, such as reverse genetics systems, genomic surveillance, and new therapeutic strategies, have added to the knowledge of the biology of JUNV and its interplay with the host immune system. Nonetheless, there are still challenges because of further spreading of the viruses among the rodents (reservoirs), inability to develop specific antiviral therapies, and the potential of other related arenaviruses. Argentine hemorrhagic fever needs to be prevented, diagnosed and controlled by further research, enhanced surveillance systems and enhanced vaccination.</p>","PeriodicalId":61903,"journal":{"name":"世界病毒学杂志(英文版)","volume":"15 3","pages":"121066"},"PeriodicalIF":0.0,"publicationDate":"2026-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13598476/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149042159","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Metagenomic next-generation sequencing in the diagnosis of viral encephalitis.","authors":"Umut Devrim Binay, Faruk Karakeçili, Orçun Barkay, Betül Sümer","doi":"10.5501/wjv.124097","DOIUrl":"10.5501/wjv.124097","url":null,"abstract":"<p><p>Viral encephalitis requires rapid etiological assessment, yet targeted polymerase chain reaction, serology, culture, and multiplex panels leave many cases unresolved because they depend on prespecified pathogens, sampling time, and specimen biology. Metagenomic next-generation sequencing (mNGS) can interrogate DNA and RNA in cerebrospinal fluid without a predefined target and may detect unexpected, rare, opportunistic, or emerging viruses. Its clinical performance, however, is not uniform. In published cohorts, diagnostic yield varies with case selection, reference standards, pathogen burden, specimen volume, pretreatment, laboratory workflow, sequencing depth, bioinformatic thresholds, and contamination control. Short-read Illumina workflows currently have the largest clinical evidence base, whereas real-time nanopore sequencing offers speed and portability but still requires site-specific validation. The strongest role for mNGS is therefore not routine first-line replacement of polymerase chain reaction or serology, but early complementary use in severe, progressive, unexplained, atypical, or immunocompromised cases after urgent targeted testing and empirical treatment have begun. A positive result requires assessment of read distribution, genome coverage, controls, clinical plausibility, and orthogonal confirmation; a negative result cannot exclude a low-titer, serology-defined, or tissue-restricted infection. This minireview critically compares the available evidence, identifies causes of between-study variation, and proposes a practical decision pathway for integrating mNGS into the diagnosis of viral encephalitis.</p>","PeriodicalId":61903,"journal":{"name":"世界病毒学杂志(英文版)","volume":"15 3","pages":"124097"},"PeriodicalIF":0.0,"publicationDate":"2026-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13598480/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149042186","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Emerging evidence of sand fly fever virus transmission in Sri Lanka.","authors":"Thulani Pattiyakumbura, Erandi Ekanayake, Nipuni Arachchige, Achini Weerathunga, Dhanushka Dasanayake, Rohitha Muthugala","doi":"10.5501/wjv.121928","DOIUrl":"10.5501/wjv.121928","url":null,"abstract":"<p><strong>Background: </strong>Sand fly fever virus (SFFV) infection is an acute self-limiting febrile illness caused by phleboviruses and transmitted by sand flies of the <i>Phlebotomus</i> species. The disease has been reported in the Mediterranean region, North Africa, the Middle East, and the Indian subcontinent, and is now considered to be expanding into new geographic areas. Clinically, SFFV infection closely resembles acute dengue fever.</p><p><strong>Aim: </strong>To detect other possible infection including SSFV in patients with clinically suspected dengue fever with negative serology results for NS1 antigen.</p><p><strong>Methods: </strong>In this study, a total of 757 serum samples were collected from patients clinically suspected of dengue fever and admitted to three major hospitals in Sri Lanka between January and August 2023. Patients were from the Colombo and Kandy District, and demographic information was obtained from laboratory request forms, although detailed individual-level demographic data were limited due to anonymization in this laboratory-based study. All samples were initially screened for dengue NS1 antigen negativity and further tested for a panel of pathogens including SFFV immunoglobulin (Ig) M, hantavirus IgM, chikungunya IgM, and leptospira IgM antibodies, as well as molecular detection of hantavirus, flavivirus, and alphavirus RNA.</p><p><strong>Results: </strong>From tested samples, two samples were serologically positive for SFFV-specific IgM using a commercial immunoblot assay, while all other tests for dengue, chikungunya, leptospira, hantavirus, and related RNA viruses were negative. These two SFFV-positive cases were from Kandy District and included one child (6-8 years) and one adult (40-50 years), both presenting with uncomplicated dengue-like illness.</p><p><strong>Conclusion: </strong>This study provides the first evidence of SFFV infection in Sri Lanka. Given the high endemicity of dengue in the country, SFFV infections may be clinically misdiagnosed as dengue and therefore remain under-recognized. Further studies involving febrile patients and sand fly vector surveillance are required to determine the true burden and epidemiological significance of SFFV in Sri Lanka.</p>","PeriodicalId":61903,"journal":{"name":"世界病毒学杂志(英文版)","volume":"15 3","pages":"121928"},"PeriodicalIF":0.0,"publicationDate":"2026-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13598478/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149042066","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"High cost of silence: Needlestick injuries and the persistence of hepatitis B virus risk among healthcare trainees.","authors":"Janaina Luz Narciso-Schiavon","doi":"10.5501/wjv.122794","DOIUrl":"10.5501/wjv.122794","url":null,"abstract":"<p><p>The study by Jaho <i>et al</i> published in the <i>World Journal of Virology</i> highlights a compelling paradox in occupational health: While a robust 86.6% of 134 Albanian health sciences students demonstrate seroprotection (antibody to hepatitis B surface antigen ≥ 10 IU/L), a staggering 64.5% report at least one needlestick injury during training. This high prevalence of exposure is compounded by a culture of silence, with one-third of incidents remaining unreported. This editorial analyzes why high seroprotection rates should not lead to institutional complacency. It argues that the specific vulnerability observed among midwifery students and the lack of systematic post-vaccination serological testing represent critical system gaps. Instead of relying solely on historical vaccination records, institutions should adopt guideline-based strategies for assessing hepatitis B immune status before clinical exposure, while fostering non-punitive reporting pathways. Bridging the gap between immunological protection and clinical behaviour is essential to safeguard those at the frontline of care.</p>","PeriodicalId":61903,"journal":{"name":"世界病毒学杂志(英文版)","volume":"15 3","pages":"122794"},"PeriodicalIF":0.0,"publicationDate":"2026-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13598479/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149042204","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Herpes zoster vaccination in inflammatory bowel disease: Evidence, guidelines, and reality.","authors":"Manish Manrai, Aditya V Pachisia, Atul A Jha, Rajat Shukla, Vivek Hande, Sandeep Thareja","doi":"10.5501/wjv.121081","DOIUrl":"10.5501/wjv.121081","url":null,"abstract":"<p><p>Patients with inflammatory bowel disease (IBD) have a 1.3-2.0 times higher risk of developing herpes zoster (HZ) compared to the general population, mainly due to immunosuppressive treatments. The risk is greatest with Janus kinase inhibitors, combination therapies, and high-dose corticosteroids, especially in younger patients with Crohn's disease. The recombinant zoster vaccine (RZV, Shingrix) provides high efficacy, with 65%-90% protection against HZ and a significant decrease in postherpetic neuralgia, along with a safety profile that does not increase IBD flares, even during immunosuppression. Guidelines from the American College of Gastroenterology, the European Crohn's and Colitis Organisation, and the Advisory Committee on Immunisation Practices strongly advise RZV for all IBD patients aged 50 and above, as well as those aged 19 and over undergoing immunomodulatory therapy. Real-world evidence supports consistent benefits across different age groups, treatments, and ethnic backgrounds. Nonetheless, there are notable implementation gaps, particularly in resource-poor Asian regions such as India, due to cost, awareness, and access constraints. Adopting a risk-gradient approach that targets high-risk individuals helps optimise resource allocation. RZV is a safe, effective, and cost-efficient method to decrease HZ-associated morbidity in IBD patients. Integrating vaccination proactively into routine IBD management is crucial to close the gap between current evidence and clinical practice.</p>","PeriodicalId":61903,"journal":{"name":"世界病毒学杂志(英文版)","volume":"15 3","pages":"121081"},"PeriodicalIF":0.0,"publicationDate":"2026-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13598481/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149042069","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Discontinuation of nucleos(t)ide analog therapy in hepatitis B e antigen-negative non-cirrhotic chronic hepatitis B patients: A real-life study.","authors":"Khellaf Amalou, Ryma Rekab, Nada Benmellouka, Boutheina Derbal, Ahlem Belloula, Hana Chetroub, Fadel Sabrina, Farid Belghanem, Khadidja Saidani","doi":"10.5501/wjv.120124","DOIUrl":"10.5501/wjv.120124","url":null,"abstract":"<p><strong>Background: </strong>The discontinuation of nucleos(t)ide analog (NUC) therapy remains controversial in hepatitis B e antigen-negative chronic hepatitis B (CHB) patients who have not attained hepatitis B surface antigen loss.</p><p><strong>Aim: </strong>To assess re-treatment rates and risk factors in non-cirrhotic hepatitis B e antigen-negative CHB patients after the cessation of NUC.</p><p><strong>Methods: </strong>Demographic, clinical, and laboratory data were prospectively collected before to and following the discontinuation of NUC.</p><p><strong>Results: </strong>Eighty-seven patients were included in the follow-up from January 2015 to September 2025; 57 were male, with a mean age of 41.3 ± 10.8 years old. The baseline median values of alanine aminotransferase (ALT) and hepatitis B viral deoxyribonucleic acid (DNA) were 87 IU/L and 37211 IU/mL, respectively. The median histologic fibrosis score was 2. The median length of treatment and consolidation therapy was 69 months and 46 months, respectively. The median duration of follow-up following the cessation of therapy was 39 months. Of the 56 patients deemed qualified for assessment based on the suggested re-treatment criteria, 29 (51.7%) underwent re-treatment. The median duration until relapse was 11 months. The cumulative virological relapse rates, defined as HBV DNA over 2000 IU/mL, were 25%, 52%, 58%, and 61% at 6 months, 12 months, 24 months, and 36 months, respectively. The cumulative retreatment rates at 6 months, 12 months, 24 months, and 36 months were 19%, 25%, 28%, and 35%, respectively. Thirty-eight patients (43%) returned to NUC treatment after an average interval of 9 months (range 1 months to 42 months). The risk factors influencing clinical relapse in patients included gender, baseline HBV DNA levels, treatment method, and ALT and aspartate aminotransferase levels at the end of treatment, Ishak fibrosis score > 2, and at the conclusion of treatment. In multivariate analysis, Ishak fibrosis score > 2 is the unique factor for retreatment.</p><p><strong>Conclusion: </strong>In resource-constrained areas, discontinuing NUC may be considered for early-stage patients with low baseline hepatitis B viral DNA and ALT levels after a lengthy consolidation treatment. A higher pretreatment liver biopsy fibrosis score predicts relapse.</p>","PeriodicalId":61903,"journal":{"name":"世界病毒学杂志(英文版)","volume":"15 3","pages":"120124"},"PeriodicalIF":0.0,"publicationDate":"2026-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13598475/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149042074","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Role of soluble human leukocyte antigen-G in virus-associated cancers: A focused minireview.","authors":"Abdellatif Bouayad","doi":"10.5501/wjv.v15.i2.120048","DOIUrl":"10.5501/wjv.v15.i2.120048","url":null,"abstract":"<p><p>Soluble human leukocyte antigen-G (sHLA-G), a non-classical major histocompatibility complex class I molecule, arises either through proteolytic cleavage of membrane-bound isoforms or <i>via</i> secretion of soluble isoforms. sHLA-G exerts potent immunosuppressive effects, facilitating immune escape of cancer cells within the tumor microenvironment by inhibiting the cytotoxic activity of natural killer cells, cytotoxic T lymphocytes, and other immune effectors. Emerging evidence indicates that aberrant expression of sHLA-G contributes to tumor progression in virus-associated malignancies, including human papillomavirus-driven cervical cancer and hepatitis B virus/hepatitis C virus-related hepatocellular carcinoma. sHLA-G is detectable in various body fluids, including plasma and serum, highlighting its potential as both a diagnostic and prognostic biomarker as well as a therapeutic target.</p>","PeriodicalId":61903,"journal":{"name":"世界病毒学杂志(英文版)","volume":"15 2","pages":"120048"},"PeriodicalIF":0.0,"publicationDate":"2026-06-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13324881/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148378255","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Human metapneumovirus infection in pregnancy: A systematic review of cohort studies and case reports.","authors":"Aikaterini Tsantila, Kleanthi Gourounti, Christina Nanou, Dimitra Metallinou, Vasiliki E Georgakopoulou, Angeliki Bolou, Athina Diamanti","doi":"10.5501/wjv.v15.i2.118445","DOIUrl":"10.5501/wjv.v15.i2.118445","url":null,"abstract":"<p><strong>Background: </strong>Human metapneumovirus (hMPV) is an important cause of acute respiratory tract infection worldwide, but its impact during pregnancy has not been systematically characterized.</p><p><strong>Aim: </strong>To synthesize available evidence on maternal, obstetric and neonatal outcomes of hMPV infection in pregnancy.</p><p><strong>Methods: </strong>Following PRISMA 2020 guidelines, a comprehensive search of PubMed/MEDLINE, EMBASE, Scopus, Web of Science and Google Scholar from inception to November 2025 identified studies reporting laboratory-confirmed hMPV infection in pregnant women. Eligible designs included case reports, case series and observational studies; however, the available evidence consisted predominantly of case reports and small case series, with only two prospective cohort studies contributing population-level data. Given anticipated heterogeneity, findings were synthesized narratively.</p><p><strong>Results: </strong>Seven studies met inclusion criteria, comprising two prospective community-based cohorts and five case reports/series. Across studies, approximately 50-60 women had laboratory-confirmed antenatal hMPV infection after exclusion of postpartum-only cases and accounting for non-overlapping cohorts. In community cohorts from Nepal and Thailand, hMPV accounted for a modest but non-trivial proportion of symptomatic antenatal respiratory illnesses, most of which were mild to moderate, self-limited, and did not require hospitalization or intensive care. In contrast, case-based reports described severe pneumonia and acute respiratory distress syndrome (ARDS) in women-typically in the second or third trimester-with underlying comorbidities such as asthma, morbid obesity, diabetes, chronic kidney disease or hypertensive disorders; no maternal deaths were reported. Obstetric outcomes were generally reassuring, although one cohort demonstrated an increased risk of small-for-gestational-age infants after antenatal hMPV infection, while evidence for preterm birth and other major complications remained limited and inconsistent. Neonatal outcomes were mostly favorable, with live births, gestational age and birthweight distributions comparable to uninfected pregnancies, and no confirmed congenital hMPV infections.</p><p><strong>Conclusion: </strong>hMPV is an under-recognized cause of respiratory illness in pregnancy, usually resulting in mild disease but occasionally associated with severe pneumonia and ARDS in women with comorbidities. A possible association with fetal growth restriction has been reported; however, given the predominance of case reports and small cohort data, causality cannot be inferred for obstetric outcomes. Evidence for other adverse maternal and neonatal outcomes remains limited and inconsistent.</p>","PeriodicalId":61903,"journal":{"name":"世界病毒学杂志(英文版)","volume":"15 2","pages":"118445"},"PeriodicalIF":0.0,"publicationDate":"2026-06-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13324766/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148378296","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Serological evidence of hepatitis B virus exposure and vaccination coverage trends in health sciences students in Albania.","authors":"Jerina Jaho, Luçiano Balilaj, Ani Bulla, Ylenia Capraro, Leonard Lamfu, Leonardo Baiocchi","doi":"10.5501/wjv.v15.i2.118992","DOIUrl":"10.5501/wjv.v15.i2.118992","url":null,"abstract":"<p><strong>Background: </strong>Hepatitis B virus remains an important occupational risk for healthcare trainees. Objective serology can verify protection and inform pre-placement clearance policies.</p><p><strong>Aim: </strong>To assess hepatitis B vaccination status, occupational exposure, and serological protection among health sciences students in Albania.</p><p><strong>Methods: </strong>Cross-sectional study (April-June 2024) at the University of Vlore. Students completed a structured questionnaire (<i>n</i> = 152); a consenting subset provided blood samples for hepatitis B surface antigen and anti-hepatitis B surface antibody (HBs) testing (<i>n</i> = 134). Group comparisons used <i>χ</i> ²/Fisher's exact tests and multivariable logistic regression for seroprotection (anti-HBs ≥ 10 IU/L).</p><p><strong>Results: </strong>All tested participants were hepatitis B surface antigen negative (<i>n</i> = 134). Overall, 86.6% had protective anti-HBs (≥ 10 IU/L), including 76.2% with titers > 100 IU/L; 13.4% had anti-HBs < 10 IU/L. Needlestick/sharps injuries were reported during training, supporting the need for standardized clearance and reporting pathways.</p><p><strong>Conclusion: </strong>Most students had serological protection, but a meaningful minority lacked protective titers. Universities and training sites should implement pre-placement HB clearance with documented vaccination, mandatory anti-HBs testing, and structured catch-up/booster pathways.</p>","PeriodicalId":61903,"journal":{"name":"世界病毒学杂志(英文版)","volume":"15 2","pages":"118992"},"PeriodicalIF":0.0,"publicationDate":"2026-06-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13324847/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148378269","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}